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Abstract
Kidney injury (deﬁned as the presence of albuminuria, proteinuria, glycosuria [without hyperglycemia], hematuria, and/or renal
hypophosphatemia) is an emerging problem in human immunodeﬁciency virus (HIV)-infected patients, although few data are available
on the role of protease inhibitors (PIs) in this condition.
To determine the time to kidney injury in a cohort of HIV-infected patients receiving a PI-containing regimen.
We report the results of a subanalysis of a published cross-sectional study. The subanalysis included only patients receiving PI-
containing regimens for more than 6 months (377 of the overall 970 patients). We determined associated factors and constructed
receiver operating characteristic curves to estimate time to kidney injury depending on the PI used.
The percentage of patients with kidney injury was 27.7% for darunavir, 27.9% for lopinavir, and 30% for atazanavir. Time to kidney
injury was as follows: 229 days for atazanavir/ritonavir (area under the curve [AUC], 0.639; sensitivity, 0.89; speciﬁcity, 0.41); 332
days for atazanavir/ritonavir plus tenofovir (AUC, 0.603; sensitivity, 0.75; and speciﬁcity, 0.29); 318 days for nonboosted atazanavir
(AUC, 0.581; sensitivity, 0.89; and speciﬁcity, 0.29); 478 days for lopinavir/ritonavir (AUC, 0.566; sensitivity, 0.864; and speciﬁcity,
0.44); 1339 days for lopinavir/ritonavir plus tenofovir (AUC, 0.667; sensitivity, 0.86; and speciﬁcity, 0.77); 283 days for darunavir/
ritonavir (AUC, 0.523; sensitivity, 0.80; and speciﬁcity, 0.261); and 286 days for darunavir/ritonavir plus tenofovir (AUC, 0.446;
sensitivity, 0.789; and speciﬁcity, 0.245). The use of lopinavir/ritonavir without tenofovir was a protective factor (odds ratio=1.772;
95%CI, 1.070–2.93; P=0.026).
For all PIs, the percentage of patients with kidney injury exceeded 27%, irrespective of tenofovir use. The longest time to kidney
injury was recorded with lopinavir/ritonavir. These results demonstrate the need for renal monitoring, including urine samples, in
patients receiving a PI-based regimen, even when tenofovir is not used concomitantly.
Abbreviations: AUC= area under the curve, eGFR= estimated glomerular ﬁltration rate, HIV= human immunodeﬁciency virus, PI
= protease inhibitor, ROC = receiver operating characteristic, TDF = tenofovir disoproxil fumarate.
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11. Introduction
Renal abnormalities (deﬁned as alteration in urine and blood
markers, i.e., presence of microalbuminuria, macroalbuminuria,
or proteinuria and/or the presence of glycosuria [without
hyperglycemia], hematuria, and/or hypophosphatemia, or an
estimated glomerular ﬁltration rate [eGFR]<60mL/min/
1.73m2) are an emerging problem in the human immunodeﬁ-
ciency virus (HIV)-infected population owing to increasing life
expectancy and prolonged exposure to antiretroviral drugs.
Prevalence is as high as 30% in some series.[1] Kidney
abnormalities usually develop slowly and silently, but can
progress to irreversible chronic disease. However, the most
relevant consequence of some alterations such as proteinuria or
altered GFR is probably the increased risk of cardiovascular
events and death.[2,3]
The relationship between antiretroviral agents and renal
abnormalities has been established mainly for tenofovir dis-
oproxil fumarate (TDF) and for its association with tubular
toxicity. TDF-related kidney injury is more likely when patients
receive concomitant protease inhibitors (PIs) owing to pharma-
cokinetic interactions.[4,5] One meta-analysis pointed to a decline
in kidney function associated with PIs, independently of
[6]
Bonjoch et al. Medicine (2016) 95:32 Medicineconcomitant use of tenofovir. Nonetheless, few data are
available on the impact of PIs on proteinuria and other signs of
kidney injury.
The aim of the present study was to determine the role of PIs
in kidney injury by evaluating time to appearance of renal
abnormalities in a cohort of HIV-infected patients receiving a PI-
containing regimen.Table 1
Patient characteristics.
Overall population N=377
Gender (male), n, % 282 (75%)
Ethnicity (white), n, % 358 (95%)
Age, years 47.45 (43–51.8)
Diabetes, n, % 11 (3%)
Hypertension, n, % 32 (8.6%)
Smoking, n, % 204 (54%)
Hepatitis B/C coinfection, n, % 119 (31.6%)
Potentially nephrotoxic concomitant therapy, n, % 47 (12.5%)
Time since diagnosis of HIV infection, years 17.3 (12–21.5)
Current CD4+T-cell count, cells/mL 553 (396–779)2. Methods
We performed a subanalysis of data collected from a cross-
sectional study.[7] Brieﬂy, the main study included 970 HIV-
infected outpatients who consecutively attended our HIV Care
Unit and agreed to participate (from January 2011 to December
2012). All the patients signed an informed consent document,
and the Institutional Ethics Committee of the hospital and the
local health authorities approved the study (code: EO-10-035).
For the subanalysis, we selected those patients who were
receiving a PI-containing regimen for more than 6 months and
had an eGFR>60mL/min/1.73m2 (377 out of 970). The
exclusion criteria included baseline renal disease, any baseline
renal alterations (baseline deﬁned as the time of the initiation of
the current antiretroviral regimen), and extra renal causes of
glycosuria and hypophosphatemia. The objective was to compare
the impact of the 3 most commonly used PIs (darunavir,
atazanavir, and lopinavir) on speciﬁc renal parameters by
estimating the predicted time to abnormality. We also deﬁned
associated risk factors.
The dose for boosted PIs was standard: atazanavir/ritonavir,
300/100mg once daily; lopinavir/ritonavir, 400/100mg twice
daily; darunavir/ritonavir 800/100mg once daily; and non-
boosted atazanavir 400mg once daily. TDF was administered at
300mg once daily.
The demographic andHIV-related data collected included time
on antiretroviral treatment, time on tenofovir, time on PIs, and
time on each speciﬁc current PI. Blood and urine samples were
collected under fasting conditions.
Kidney injury was deﬁned as the presence of micro- or
macroalbuminuria or proteinuria, that is, an albumin/creatinine
ratio of >30mg/g and/or protein/creatinine ratio of >200mg/g
and/or the presence of glycosuria (without hyperglycemia),
hematuria, and/or hypophosphatemia (<2.5mg/dL).[8]
Concomitant use of TDF was deﬁned as exposure to the drug
for more than 6 months. Patients were considered not to have
received TDF if they had never received it, had received it for less
than 3 months, or if they had discontinued it for more than 4
months considered the mean time for reversibility of TDF-related
toxicity, as is described in a previous study on the reversibility of
TDF-related toxicity.[9]Nadir CD4+T-cell count, cells/mL 181 (92–276.5)
Suppressed viral load, n, % 323 (85.6%)
Time on ARV treatment, months 171 (108–209.6)
Time on PIs, months 103.2 (62–144)
Time on TDF, months 32.3 (17.8–49.7)
Time on ATZ (without TDF), months 17.5 (7.3–28.3)
Time on ATZ+TDF, months 32.5 (8.4–45.2)
Time on LPV (without TDF), months 28.9 (15.6–41.9)
Time on LPV+TDF, months 44.1 (25.7–54.7)
Time on DRV (without TDF), months 16.1 (9.6–25.4)
Time on DRV+TDF, months 16.5 (9.9–33.5)
Data are expressed as the median (IQR) unless otherwise indicated. ARV= antiretroviral, ATZ=
atazanavir, DRV=darunavir, IQR= interquartile range, LPV= lopinavir, n=number of patients, PI=
protease inhibitor, TDF= tenofovir.2.1. Statistical analyses
Continuous variables were expressed as median (interquartile
range), and categorical variables were expressed as frequency
(percentage), unless stated otherwise.
Receiver operating characteristic (ROC) curves were used to
calculate a cut-off for time on treatment according to the presence
or absence of kidney injury. The time for the decision threshold
was selected by setting a minimum sensitivity of 80% and the
largest speciﬁcity available. An area under the curve (AUC) of
0.5 was considered a random allocation; an AUC greater than
0.5 was considered acceptable as a sign of possible relationship.
Statistical signiﬁcance was set at 0.05.2All candidate predictor variables were entered in a logistic
regression analysis, with kidney injury (as deﬁned above) as the
dependent variable. The variables included in the logistic
regression analysis were time on PIs with and without TDF,
time on TDF, time on nucleoside reverse-transcriptase inhibitors,
current use of each PI, current use of TDF, age, time since
diagnosis of HIV infection (it is deﬁned as the date of the 1st
positive HIV test result), time on antiretroviral therapy, age,
current and nadir CD4+cell count, undetectable viral load,
hepatitis coinfection, use of nephrotoxic drugs, and body mass
index. Variables with a P-value <0.20 were entered into the
multivariate model. Backward selection (Wald test) was used to
build the multivariate model. Forward selection was subsequent-
ly applied to verify the stability of the results. Multicolinearity
was avoided by excluding from the multiple regression 2
covariates with a correlation coefﬁcient >75%.
All analyses were performed using SPSS (version 15.0; SPSS
Inc, Chicago, IL).
3. Results
Of the 377 patients included, 104 (29.4%) were receiving
lopinavir/ritonavir-containing regimens,with andwithout TDF, in
28 and 76 cases, respectively; 177 patients (50%) were receiving
darunavir/ritonavir, with and without TDF, in 68 and 99 cases;
and 73 (20.6%) were receiving atazanavir/ritonavir, with and
without TDF, in 30 and 43 cases, respectively. Only 23 patients
were receiving nonboosted atazanavir without TDF in all cases.
The demographic and clinical characteristics of the patients
and the time on the speciﬁc PI are shown in Table 1. Potentially
nephrotoxic drugs were collected: angiotensin-converting en-
zyme inhibitors, angiotensin receptor blockers, cyclosporine,
nonsteroidal antiinﬂammatory drugs, and tacrolimus. After a
median (interquartile range) time on the PI of 103 (62–144)
months, the percentage of patients fulﬁlling the criteria for kidney
injury (as deﬁned above) was 27.7% for darunavir (27.9% with
Bonjoch et al. Medicine (2016) 95:32 www.md-journal.comand 30.3% without TDF), 27.9% for lopinavir (25% with and
29% without TDF), and 30% for atazanavir (20% with and
45% without TDF). No statistically signiﬁcant differences were
observed when we compared each PI with and without TDF.
Similarly, no signiﬁcant differences were observed when we
compared all the PIs with TDF and without TDF.
Overall, altered protein/creatinine and/or albumin/creatinine
ratios were the most frequent alteration detected (65% of all
alterations).
The ROC curve analysis (Fig. 1) showed an estimated time to
kidney injury of 229 days for atazanavir/ritonavir when it was
used without TDF (sensitivity, 0.89; speciﬁcity, 0.41; and AUC,
0.639), 332 days when it was administered with TDF (sensitivity,
0.75; speciﬁcity, 0.29; and AUC, 0.603), and 318 days when
nonboosted atazanavir was administered without TDF (sensitiv-
ity, 0.89; speciﬁcity, 0.29; and AUC, 0.581).
Time until kidney injury was 478 days for lopinavir/ritonavir
without TDF (sensitivity, 0.864; speciﬁcity, 0.44; and AUC,
0.566) and 1339 days for lopinavir/ritonavir plus TDF
(sensitivity, 0.86; speciﬁcity, 0.77; and AUC, 0.667).
Estimated time to kidney injury was 283 days for darunavir/
ritonavir without TDF (sensitivity, 0.80; speciﬁcity, 0.261; andLopinavir/ritonavir Atazana
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Figure 1. ROC curve is using the top discriminatory features of time on different P
having developed kidney injury. (A) Boosted PIs without TDF; (B) boosted PIs plu
tenofovir).
3AUC, 0.523) and 286 days for darunavir/ritonavir plus TDF
(sensitivity, 0.789; speciﬁcity, 0.245; and AUC, 0.446).
The only factor in the logistic regression analysis that was
associated with a decrease in the risk of renal abnormalities was
current use of lopinavir/ritonavir without TDF (odds ratio=
1.772; 95%CI, 1.070–2.93; P=0.026). No other correlations
were established.4. Discussion
We determined predicted time to kidney injury to analyze the
impact of various PIs on renal alterations inHIV-infected patients
with an eGFR>60mL/min/1.73m2. Abundant recent data are
available for PIs and renal abnormalities[10,11]; however, few data
have been reported on the impact of these agents on kidney
injury, deﬁned as proteinuria, hematuria, glycosuria, and/or
hypophosphatemia.[12]
The importance of an early detection of abnormal biomarkers
related with renal damage in the 1st stages, before the advent of
clinical symptoms, lies in the possible link with the reversibility of
the damage. The safety proﬁle of TDF has been well studied, invir/ritonavir Darunavir/ritonavir 
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strategies.
The 1st remarkable ﬁnding of this study is the longer time to
kidney injury with lopinavir (478 and 1339 days without and
with TDF, respectively). Time to kidney injury was much shorter
for the remaining PIs (229 and 332 days for atazanavir and 283
and 286 days for darunavir, without andwith TDF, respectively),
although the AUC was less accurate in the case of darunavir.
These results could reﬂect lower renal toxicity with lopinavir than
with the other PIs, as corroborated by the results of the logistic
regression.
Also interesting was the considerably high proportion of
patients (30%, similar for all 3 agents) who developed kidney
injury, even when TDF was not used concomitantly. This result
seems to contradict the results of the logistic regression analysis
with respect to lopinavir and the ROC curves with respect to the
time taken to develop kidney injury in the case of lopinavir.
Nevertheless, compared with the other PIs, exposure to lopinavir
was longer, although the number of renal abnormalities was
similar to that of the other drugs.
Our results agree with those of previous studies in that the
worst result (deﬁned as the shortest time to development of
alterations in urinary markers) was with atazanavir/ritonavir,
followed by lopinavir/ritonavir.[10,11,13] Few data are available
on the use of darunavir/ritonavir.[14] Nevertheless, these studies
assessed changes in eGFR, incidence of chronic kidney disease, or
both, but not the presence of proteinuria or other signs of kidney
injury. Atazanavir in particular has the potential to yield
crystalline precipitate in urine, leading to crystalluria, tubuloin-
terstitial nephritis, and acute or chronic kidney disease.[15] In the
case of lopinavir/ritonavir, the mechanism that leads to a decline
in the eGFR remains unclear, since the results vary depending on
the equation used, although ritonavir could play a role in the
inhibition of the transport protein of tenofovir.[10] In addition,
lopinavir-related acute interstitial nephritis was recently
reported.[16] Darunavir has only been associated with asymp-
tomatic nephrolithiasis,[17] although it is the drug with shortest
follow-up.
Previous studies conﬁrm increased toxicity of TDF when
administered concomitantly with boosted PIs.[4,18] This effect is
related to inhibition of multidrug resistance-associated protein 4
by ritonavir, the subsequent increase in intracellular tenofovir
concentrations, and the greater inhibition of DNA-Y polymerase
and depletion of mitochondrial DNA.[19,20] Nevertheless, in our
study, time to kidney injury was longer in patients receiving
lopinavir or atazanavir concomitantly with TDF. These ﬁndings
should be interpreted with caution owing to the small sample size
in both groups (only 27 and 28 patients with atazanavir and
lopinavir, respectively, were also receiving TDF) and to the
process for selection of patients, which focused on PIs. The
selection criteria excluded patients receiving TDF but not PIs,
patients with less than 6 months’ exposure to TDF, patients who
discontinued the drug early (3 months), and patients who had
interrupted therapy for more than 4 months. The selection
process excluded subjects with early toxicity associated with
TDF, although it could lead us to underestimate the impact of the
drug on kidney markers and thus restrict conclusions about TDF
as a separate agent.
Our study has several limitations. Its cross-sectional design
could lead us to overestimate the prevalence of kidney injury,
because only 1 blood parameter and 1 urine parameter were
determined. In addition, no follow-up was available to assess4outcome, and no data were recorded for previous antiretroviral
history or previous toxicity. Since we included mainly white
men, our results cannot be extrapolated to other populations.
Statistical methods that include time, such as a Cox model, could
not be used owing to the cross-sectional design of the study.
Finally, the ROC curve analysis did not show correlations in all
cases (e.g., darunavir), probably because the number of patients
included or the duration of the evaluation was insufﬁcient.
To conclude, our study identiﬁed a considerable proportion of
patients with signs of kidney injury while receiving PI-based
regimens. The longest time to kidney injury was recorded for
lopinavir/ritonavir. Although further longitudinal studies are
needed to conﬁrm the long-term consequences of these ﬁndings,
our results have a key clinical implication: give the high
prevalence of renal abnormalities and the recognized silent
nature of the initial phases of kidney injury it is important to
stress the need to monitor renal parameters, including urine
values, even in patients not receiving concomitant tenofovir.Acknowledgements
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